Immunogenicity: Implications for rheumatoid arthritis treatment

Bulletin of the Hospital for Joint Diseases

Volumn 71, Issue 3, 2013, Pages 200-203

  Solomon, Gary ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB;

ARTICLE; BIOLOGICAL THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; INCIDENCE; PSORIASIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONDYLARTHRITIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL PRODUCTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 84886483746     PISSN: 23284633     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ebert EC, Das KM, Mehta V, Rezac C. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol. 2008 Dec;154(3):325-31. doi: 10.1111/j.1365-2249.2008.03773.x. Epub 2008 Sep 23.
2. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009 Nov;68(11):1739-45. doi: 10.1136/ard.2008.092833. Epub 2008 Nov 19.
3. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with a loss of response to antitumour necrosis factoralpha therapy in psoriasis: a retrospective, observational study. Br J Dermol. 2010 Apr;162(4):780-5. doi: 10.1111/j.1365-2133.2009.09563.x. Epub 2009 Oct 26.
4. Yukawa N, Fujii T, Kondo-Ishikawa S, et al. Correlation of antinuclear antibody and anti-double stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther. 2011;13(6):R213. doi: 10.1186/ar3546. Epub 2011 Dec 22.
5. Danes S, Fiorino G, Reinsch W. Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther. 2011 Jul;34(1):1-10. doi: 10.1111/j.1365-2036.2011.04679.x. Epub 2011 May 3.
6. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):19-22.
7. Maneiro JR, Salgado E, Gomex-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune mediated inflammatory conditions: systemic review and meta-analysis. JAMA Intern Med. 2013 Jun 24:1-13. doi: 10.1001/jamainternmed.2013.7430. [Epub ahead of print]
8. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013 Jul 26. [Epub ahead of print]
9. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune mediated inflammatory diseases: a systemic review of the literature with a meta-analysis. Ann Rheum Dis. 2012 Dec 6. [Epub ahead of print]
10. Krieckaert Cl, Numohamet MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012 Nov;71(11):1914-5. doi: 10.1136/annrheumdis-2012-201544. Epub 2012 May 14.
11. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immonomodulators on the immunogenicity of TNFblocking monoclonal antibodies: a review. Arthritis Res Ther. 2010;12(5):217. doi: 10.1186/ar3147. Epub 2010 Oct 20.
12. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2013 Aug 14. [Epub ahead of print]
13. Plasencia C, Pascula-Salcedo D, Nuño L, et al. Influence of immunogenicity on the effect of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012 Dec;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828. Epub 2012 May 6.
14. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008 Feb 15;59(2):234-40. doi: 10.1002/art.23333.
15. Humira (adalimumab) package insert. Abbott Park, Illinois: Abbott Laboratories. Available at www.humira.com. Accessed September 12, 2013.
16. Garcês S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitior therapies. Ann Rheum Dis. 2013 May 11. [Epub ahead of print]
17. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.